In Brief: PathoGenesis Corp.
PathoGenesis Corp.: Infectious disease R&D firm completes initial public offering of 3 mil. shares at $10 per share on Nov. 22, the Seattle-based firm announces. The company has granted its underwriter Prudential Securities the option to purchase an additional 450,000 shares of stock in a 30-day over-allotment clause. PathoGenesis' lead compound, TOBI for treatment of chronic lung infections in cystic fibrosis patients, began Phase III trials in the U.S. in July...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth